Designations: |
CTLA4 Ig-24 |
Depositors: |
Bristol-Myers Squibb Co. |
Biosafety Level: |
1 |
Shipped: |
frozen |
Medium & Serum: |
See Propagation |
Growth Properties: |
adherent |
Organism: |
Cricetulus griseus (hamster, Chinese) |
Morphology: |
CRL-10762 CTLA4 Ig-24 仓鼠卵巢细胞epithelial
|
Source: |
Organ: ovary |
Permits/Forms: |
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
|
Gender: |
female |
Comments: |
The line was constructed by transfecting CHO cells with a construct (CTLA4Ig) containing the sequence for the extracellular domain of the human CTLA-4 gene fused to the sequence for the hinge, CH2 and CH3 regions of human IgC.gamma.1 domain.The cells express the fusion protein (CTLA4Ig).
The cells express the fusion protein (CTLA4Ig). |
Propagation: |
ATCC complete growth medium: Dulbecco's modified Eagle's medium with 0.2 mM proline, 0.001 mM methotrexate, 90%; fetal bovine serum, 10%
Temperature: 37.0°C |
Subculturing: |
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week
Remove medium, add fresh 0.25% trypsin solution for 1 to 2 minutes, remove trypsin and let the culture sit at room temperature until the cells detach. Add fresh medium, aspirate and dispense into new flasks. |
References: |
4548: Linsley PS. Chimeric CTLA4 receptor and methods for its use. US Patent 5,434,131 dated Jul 18 1995 |